Human umbilical cord mesenchymal stem cells promoted tumor cell growth associated with increased interleukin-18 in hepatocellular carcinoma

Background Hepatocellular carcinoma (HCC) is experiencing a concerning rise in both incidence and mortality rates. Current therapeutic strategies are limited in their effectiveness, largely due to the complex causes of the disease and significant levels of drug resistance. Given the latest developments in human umbilical cord mesenchymal stem cells (hUC-MSCs) research, there is a debate over the continued use of stem cell transplantation for treating tumors. Consequently, this study seeks to explore the role of hUC-MSCs in the management of HCC. Methods and results HUC-MSCs increased the number (10.75 +/- 1.50) in the DEN/TCPOBOP-induced mice hepatoma model, compared with DMSO group (7.25 +/- 1.71). Moreover, the liver index in hUC-MSCs group (0.21 +/- 0.06) was greater than that in DMSO group (0.09 +/- 0.01). Immunohistochemical (IHC) analysis revealed that while hUC-MSCs did not alter Foxp3 expression, they significantly stimulated Ki67 expression, indicative of increased tumor cellular proliferation. Additionally, immunofluorescence (IF) studies showed that hUC-MSCs increased CD8+ T cell counts without affecting macrophage numbers. Notably, granzyme B expression remained nearly undetectable. We observed that serum IL-18 levels were higher in the hUC-MSCs group (109.66 +/- 0.38 pg/ml) compared to the DMSO group (91.14 +/- 4.37 pg/ml). Conversely, IL-1 beta levels decreased in the hUC-MSCs group (63.00 +/- 0.53 pg/ml) relative to the DMSO group (97.38 +/- 9.08 pg/ml). Conclusions According to this study, hUC-MSCs promoted the growth of liver tumors. Therefore, we proposed that hUC-MSCs are not suitable for treating HCC, as they exhibit clinically prohibited abnormalities.